Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
The New England Journal of Medicine|July 29, 1999
Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting InvestigatorsA M Lincoff, R M Califf, D J Moliterno, et al.
The Annals of Thoracic Surgery|September 2, 2000
Abciximab and bleeding during coronary surgery: results from the EPILOG and EPISTENT trials. Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibition in STENTingA M Lincoff, L A LeNarz, G J Despotis, et al.
Circulation|April 20, 1999
Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockadeA M Lincoff, J E Tcheng, R M Califf, et al.
The American Journal of Cardiology|February 1, 1997
Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. PROLOG InvestigatorsA M Lincoff, J E Tcheng, R M Califf, et al.
Pageof 2